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Adding a single low-dose of primaquine 
(0.25 mg/kg) to artemether-lumefantrine 
did not compromise treatment outcome 
of uncomplicated Plasmodium falciparum 
malaria in Tanzania: a randomized, 
single-blinded clinical trial
Richard Mwaiswelo1, Billy Ngasala1*, Irina Jovel2, Berit Aydin‑Schmidt2, Roland Gosling3,4, Zul Premji5, 
Bruno Mmbando6, Anders Björkman2 and Andreas Mårtensson7
Abstract 
Background: The World Health Organization (WHO) recently recommended the addition of a single low‑dose of the 
gametocytocidal drug primaquine (PQ) to artemisinin‑based combination therapy (ACT) in low transmission set‑
tings as a component of pre‑elimination or elimination programmes. However, it is unclear whether that influences 
the ACT cure rate. The study assessed treatment outcome of artemether‑lumefantrine (AL) plus a single PQ dose 
(0.25 mg/kg) versus standard AL regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in 
Tanzania.
Methods: A randomized, single‑blinded, clinical trial was conducted in Yombo, Bagamoyo district, Tanzania. Acute 
uncomplicated P. falciparum malaria patients aged ≥1 year, with the exception of pregnant and lactating women, 
were enrolled and treated with AL plus a single PQ dose (0.25 mg/kg) or AL alone under supervision. PQ was admin‑
istered together with the first AL dose. Clinical and laboratory assessments were performed at 0, 8, 24, 36, 48, 60, and 
72 h and on days 7, 14, 21, and 28. The primary end‑point was a polymerase chain reaction (PCR)‑adjusted adequate 
clinical and parasitological response (ACPR) on day 28. Secondary outcomes included: fever and asexual parasitaemia 
clearance, proportion of patients with PCR‑determined parasitaemia on day 3, and proportion of patients with Pfmdr1 
N86Y and Pfcrt K76T on days 0, 3 and day of recurrent infection.
Results: Overall 220 patients were enrolled, 110 were allocated AL + PQ and AL, respectively. Parasite clearance by 
microscopy was fast, but PCR detectable parasitaemia on day 3 was 31/109 (28.4 %) and 29/108 (26.9 %) in patients 
treated with AL + PQ and AL, respectively (p = 0.79). Day 28 PCR‑adjusted ACPR and re‑infection rate was 105/105 
(100 %) and 101/102 (99 %) (p = 0.31), and 5/107 (4.7 %) and 5/8 (4.8 %) (p = 0.95), in AL + PQ and AL arm, respec‑
tively. There was neither any statistically significant difference in the proportion of Pfmdr1 N86Y or Pfcrt K76T between 
treatment arms on days 0, 3 and day of recurrent infection, nor within treatment arms between days 0 and 3 or day 0 
and day of recurrent infection.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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Background
Artemisinin-based combination therapy (ACT) is gen-
erally recommended as first-line treatment for uncom-
plicated Plasmodium falciparum malaria globally [1]. 
Recently, the World Health Organization (WHO) has 
recommended the addition of a 0.25 mg/kg single-dose of 
the gametocytocidal drug primaquine (PQ) to standard 
ACT regimen as a component of pre-elimination or elim-
ination of malaria in low-intensity transmission settings 
and for containment in areas threatened by artemisinin 
resistance [2, 3]. Most concerns with this new recom-
mendation have been on safety, due to the potential risk 
of PQ-induced haemolysis in glucose-6-phosphate dehy-
drogenase (G6PD)-deficient patients. Equally important 
is to ensure that the treatment outcome of ACT is not 
compromised by the addition of a single-low dose of PQ. 
This is of particular concern since the individual patient 
with uncomplicated malaria does not personally benefit 
from PQ intake, the potential benefits, i.e., of reduced 
transmission, are rather on community level. However, 
no study has reported on the cure rate of ACT in addi-
tion to 0.25 mg/kg single-dose PQ.
Anti-malarial drug efficacy depends upon appropri-
ate drug levels being reached and maintained for a long 
enough time for the drug to act [4]. Insufficient expo-
sure is associated with increased risk of treatment fail-
ure. Inhibition of drug metabolism through drug–drug 
interaction may lead to insufficient exposure and conse-
quently reduced efficacy [4, 5]. However, comprehensive 
data on potential interactions between artemether-lume-
fantrine (AL) and PQ are currently lacking, and therefore 
it remains unclear whether the addition of this single 
low-dose (0.25 mg/kg) PQ may compromise the efficacy 
of AL [6].
The aim of this study was to assess treatment outcome 
of the recent WHO recommendation of adding a single 
PQ dose (0.25  mg/kg) to AL versus standard AL regi-




This trial was conducted at Yombo primary health facility, 
Bagamoyo district, Tanzania, between July and Novem-
ber, 2014. The health facility is located southwest, about 
20  km, from Bagamoyo town. It serves approximately 
7000 people and has capability to carry out routine 
malaria microscopy and rapid diagnostic test.
Malaria transmission is high and occurs throughout the 
year with peaks related to the long rain season from May 
to July and short rain season from November to Decem-
ber. In the study area, P. falciparum is the major malaria 
species and Anopheles gambiae sensu stricto the main 
vector [7–9]. AL has been used as the first-line treat-
ment for uncomplicated malaria since 2006. Sulfadox-
ine-pyrimethamine is used for intermittent preventive 
treatment in pregnant women. Long-lasting, insecticide-
treated mosquito nets is the major vector control method 
[10]. G6PD deficiency prevalence in the study area has 
previously been estimated to 13.6 % in hemizygous males 
and 4.5 % in homozygous females [11].
Study design
This was a randomized, single-blinded, clinical trial com-
paring treatment outcome and safety of AL plus a single 
low-dose PQ (AL  +  PQ) versus standard AL regimen. 
Safety outcomes have been presented in a separate publi-
cation [11]. Patients with uncomplicated microscopically 
confirmed P. falciparum mono-infection were enrolled, 
randomly assigned to either AL + PQ or AL treatment, 
admitted during the first 3 days of treatment and there-
after followed up until day 28 after treatment initiation.
Treatment outcome was based on polymerase chain 
reaction (PCR)-adjusted parasitological cure. Thera-
peutic failures were classified as; early treatment failure 
(ETF), late clinical failure (LCF), or late parasitological 
failure (LPF) [12].
Study population
Patients presenting at the study site with suspected acute 
uncomplicated malaria were screened for eligibility. 
Inclusion criteria were age ≥1 year, weight ≥10 kg, body 
temperature ≥37.5 °C or history of fever in the last 24 h, 
microscopy confirmed P. falciparum mono-infection, any 
parasitaemia level, ability to swallow oral medication, 
ability and willingness to abide by the study protocol and 
the stipulated follow-up visits, and a written informed 
consent (in case of children a proxy consent from a par-
ent/guardian). Exclusion criteria were evidence of severe 
malaria or danger signs, known allergy to trial medi-
cines, reported anti-malarial intake ≤2 weeks, haemoglo-
bin (Hb) <8 g/dL, blood transfusion within last 90 days, 
Conclusion: The new WHO recommendation of adding a single low‑dose of PQ to AL did not compromise treat‑
ment outcome of uncomplicated P. falciparum malaria in Tanzania.
Trial registration number NCT02090036
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febrile condition other than malaria, known underlying 
chronic or severe disease (including severe malnutrition), 
pregnancy and breastfeeding.
Randomization and blinding
Treatment allocation was done using sex-stratified, block 
randomization with four blocks, two per treatment arm 
using RESEARCH RANDOMIZER (version 4) (computer 
software) (Wesleyan University, Connecticut, USA) [13].
Opaque envelopes containing the pre-determined 
treatment codes were kept serially in a male and female 
strata. The envelopes were opened by a study nurse just 
before the first treatment dose was administered. Patients 
were blinded to the assigned treatment.
Treatment
A standard, weight-based, three-day course of AL 
(Coartem®, Novartis) was administered to all patients 
according to Tanzania national treatment guideline for 
uncomplicated P. falciparum malaria [14]. AL dispers-
ible tablets suspended in water were administered to 
children who were not able to swallow tablets. A single 
0.25  mg/kg PQ dose (Primaquine phosphate, Sanofi) 
was administered together with AL first dose to patients 
assigned AL + PQ treatment. The accuracy of PQ dose 
among patients weighing less than 60 kg body weight was 
ensured by administering the drug in aqueous solution, 
whereas for adults weighing 60  kg and above the drug 
was administered as tablet. To make aqueous solution, a 
15 mg PQ tablet was suspended in 15 mL of water, and 
the dose was measured using a sterile syringe based on 
body weight. To achieve the single blinding, the PQ dose 
was prepared in the absence of patients, and a glucose-
based syrup was added to mask the PQ taste, whereas 
for patients allocated AL alone, the same glucose-based 
syrup was administered with AL first dose. Adult patients 
allocated to the AL + PQ arm, during consenting, never 
knew in which treatment arm they were allocated, and 
during drug administration, PQ tablet was mixed with 
AL tablets, however, in case patients asked about the 
additional tablet, they were told that the tablet was given 
to prevent treatment side effects. In order to optimize 
AL absorption and minimize PQ gastro-intestinal side 
effects, biscuits were administered prior to all drug doses 
[15]. A study nurse administered/supervised intake of 
all drug doses. Patients were monitored for 30 min after 
each drug dose. Treatment was re-administered in case 
of vomiting within this period.
Lost follow‑up and patient withdrawal
Study withdrawal criteria were: vomiting the trial medi-
cine >three times, withdrawal of consent, intake of any 
medicine with anti-malarial properties outside the study 
protocol, or any protocol violation. Subjects were consid-
ered lost to follow-up and consequently withdrawn if they 
missed a scheduled follow-up visit and did not attend on 
the successive days despite efforts to trace them at their 
homes [12]. A subject who returned before the last day of 
follow-up was not considered a lost follow-up. Subjects 
with symptoms/signs of severe disease (including repeti-
tive vomiting of trial medicine) were treated according 
to the national guideline and were then followed up until 
recovery.
Procedures
Clinical assessment was performed at 0, 8, 24, 36, 48, 
60, and 72 h and on days 7, 10, 14, 21, 28 or on any day 
of recurrent illness. The assessment included history of 
clinical symptoms, possible adverse events, concomitant 
drug consumption and clinical examination including 
measurement of axillary temperature. Fever was defined 
as body temperature ≥37.5  °C. A case record form was 
used to record all clinical and laboratory data. Laboratory 
assessment involved collection of finger-prick blood sam-
ples for Hb concentration, thick smears for microscopy-
determined asexual and sexual parasitaemia, thin smears 
for species determination (at enrolment) and filter-paper 
blood samples for parasite detection and genotyping by 
PCR. Hb assessment was done on days 0, 1, 2, 3, 7, 10, 14, 
21, 28 or on any day of recurrent illness, whereas, filter 
paper and blood slide samples were collected at 0, 8, 24, 
36, 48, 60, and 72 h and on days 7, 10, 14, 21, 28 or on any 
day of recurrent illness. Hb concentration was measured 
using a portable spectrophotometer, HemoCue Hb 201+ 
(HemoCue AB, Ängelholm Sweden), with a precision 
of ±0.3  g/dL. A control cuvette at 16.0 ±  0.3  g/dL was 
used for daily calibration according to manufacturer’s 
instruction.
A 10  % Giemsa solution was used to stain thick and 
thin blood smears. Thin smears were prepared once, i.e., 
at enrolment, whereas thick smears were prepared at all 
sampling time points. Asexual parasites were counted 
against 200 white blood cells (WBC). The obtained num-
ber was multiplied by 40, assuming 8000 leukocytes 
per μL of blood, to gain an approximate parasite count. 
In case no parasites were observed after examining 100 
fields, the blood slide was considered negative. Each slide 
was read by two independent microscopists. In case they 
disagreed on presence of parasitaemia or if density dif-
fered by more than 25 %, a third independent reading was 
performed. In case of positive versus negative results, a 
third independent reading was used to confirm the read-
ing of the first two readers. The filter paper (3MM What-
man) blood samples were labelled, air-dried at room 
temperature for 3–4  h and then packed in individual 
plastic bags and stored. After study completion, all filter 
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papers were transported to Karolinska Institutet, Swe-
den, for molecular analysis.
Molecular analysis
A 10 % Chelex-100® method was used to extract genomic 
DNA from dried blood spots [16]. Paired blood samples 
(pre-treatment and day of recurrent parasitaemia) from 
patients classified as LCF or LPF were genotyped to dif-
ferentiate recrudescence from re-infection by stepwise 
genotyping of P. falciparum block 3 of merozoite surface 
protein (msp) 2, block 2 of msp 1 and region II (RII) of 
glutamate-rich protein (glurp) [17]. The respective initial 
amplifications were followed by individual nested PCR 
reactions using family specific primers for msp1 (K1, 
MAD20 and RO33) and msp2 (FC27 and IC) and semi-
nested for RII of glurp [17]. The amplicons were loaded 
on a GelRed™ (Biotium, Hayward, CA, USA) stained aga-
rose gel, separated by electrophoresis and then visualized 
under ultraviolet transillumination (Gel Doc™, Bio-Rad, 
Hercules, CA, USA), and sized by Image Lab™ software 
(Bio-Rad, Hercules, CA, USA). Alleles in each family 
were considered the same if fragments size were within 
20 base pair interval. Subjects with recurrent parasitae-
mia by microscopy, which could not be confirmed by 
PCR were considered to have uncertain-PCR-adjusted 
outcome.
Recrudescence was defined as presence of at least one 
matching allelic band, and re-infection was defined as 
absence of any matching allelic band at baseline and on 
the day of parasite recurrence [17]. In addition, P. falcipa-
rum multi-drug resistant gene 1 (Pfmdr1) asparagine (N)-
86-tyrosine (Y) and chloroquine resistance transporter 
gene (Pfcrt) lysine (K)-76-threonine (T) were genotyped 
using nested PCR followed by restriction fragment length 
polymorphism using ApoI restriction enzyme as previ-
ously described [18].
Study end‑points
The primary outcome was the proportion of patients 
with PCR-adjusted adequate clinical and parasitologi-
cal response (ACPR) by day 28. Secondary outcomes 
included: fever and asexual parasite clearance, propor-
tion of patients with PCR-determined parasitaemia on 
day 3, PCR- determined re-infection rate, and proportion 
of patients with Pfmdr1 N86Y and Pfcrt K76T on days 0, 
3 and day of recurrent infection.
Statistical analysis
Sample size calculation was based on equivalence, 
defined as margin of 10 % PCR-adjusted ACPR, between 
the treatments. Allowing for 10 % attrition, 80 % power 
at 0.05 significance, a sample size of 110 per treatment 
arm was required. Data were double-entered in an elec-
tronic database and analysed using SPSS software version 
16 (SPSS Inc, Chicago, USA) as per protocol. Independ-
ent sample t test was used to compare means. Non-para-
metric data were compared using Chi square, Fisher’s or 
McNemar tests as appropriate. Cure rate end points were 
analysed by survival analysis, and the survival curves of 
the two treatment arms were plotted and compared using 
log-rank test. Data were censored at the time of with-
drawal for patients lost to follow up, withdrew consent 
and PCR determined re-infection or uncertain PCR out-
come. A p ≤ 0.05 was considered significant.
Results
Patients’ characteristics and trial profile
The flow of patients through the trial is presented in 
Fig. 1. In summary, a total of 1065 subjects were screened 
for eligibility, of whom 845 were not included. The 
remaining 220 were enrolled, 110 per treatment arm. 
Pre-treatment characteristics of the study participants 
are presented in Table 1.
Treatment outcomes
Treatment outcomes are presented in Table 2 and Fig. 2. 
There was no statistically significant difference in the 
cure (p  =  0.31) or re-infection rates (p  =  0.95) by day 
28 between the treatment arms. The survival curves for 
the cure rate were not statistically significant different 
(p = 0.94). 
Gametocyte carriage
Microscopic gametocytaemia was only detected in one 
patient at enrolment and in two patients at 24  h, both 
treated with AL  +  PQ. Thereafter, no gametocyte car-
riage was detected.
Parasite and fever clearance
Microscopy-determined asexual parasite and fever clear-
ance was rapid and similar across treatment arms (Figs. 3 
and 4). No parasite carriage was observed after 36 and 
48 h in AL + PQ and AL arm, respectively.
PCR detectable parasitaemia on day 3
On day 3, PCR detectable parasitaemia was found in 
31/109 (28.4 %) and 29/108 (26.9 %) patients treated with 
AL + PQ and AL, respectively (p = 0.79).
Prevalence of Pfmdr1 N86Y and Pfcrt K76T
The distribution of Pfmdr1 N86Y and Pfcrt K76T on days 
0, 3 and day of recurrent infection across treatments is 
presented in Table  3. There was neither any statistically 
significant difference in the proportion of Pfmdr1 N86Y 
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or Pfcrt K76T between treatment arms on days 0, 3 and 
day of recurrent infection, nor within treatment arms 
between days 0 and 3 or day 0 and day of recurrent infec-
tion. Pooling of all 220 patients did not result in a sta-
tistically significant selection in Pfmdr1 N86 (p =  0.07, 
McNemar test) or Pfcrt K76 (p =  0.25, McNemar test) 
between days 0 and 3, or between day 0 and day of recur-
rent infection [Pfmdr1 N86 (p  =  1.0, McNemar test), 
Pfcrt K76 (p = 1.0, McNemar test)].
Discussion
This study provides much needed data on treatment 
outcome of the new WHO recommendation of adding 
a single low-dose (0.25  mg/kg) of PQ to AL compared 
with standard AL treatment alone. Both regimens pro-
vided high cure rates for the treatment of acute uncom-
plicated P. falciparum malaria in Tanzania, with similar 
PCR-ACPR as previously has been reported from the 
same study area of AL alone [19–21], and that of other 
Fig. 1 Flow of patients through the trial
Table 1 Pre-treatment characteristics of the study subjects
‡ Mann–Whitney test, † Student t-test, ¥ Chi square test
Characteristic Treatment arm P‑value
AL + PQ AL
n = 110 n = 110
Female, n (%) 55 (50) 55 (50) 1.0
Age (years), median (range) 9 (5.6–15) 10 (5–23) 0.392‡
Body weight (kg), mean (SD) 30.7 (17.1) 34.3 (19.6) 0.145†
Body temperature (°C), mean (SD) 38.3 (1.1) 38.3 (1.3) 0.977†
Fever (≥37.5 °C), n (%) 88 (80) 80 (73) 0.204¥
Geometric mean asexual parasite density/µl (95 % CI) 8327 (5451–12,717) 8384 (5437–12,927) 0.982†
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previously reported studies on AL plus 0.75, 0.4 or 
0.1  mg/kg single-dose PQ [15, 22]. Similar crude cure 
rates and PCR-determined re-infection rates were also 
found between the treatment arms. Moreover, asexual 
parasite clearance was rapid in both arms. However, a 
relatively large, but equal, proportion of patients across 
treatment arms had PCR-detectable parasitaemia on day 
3. These findings therefore suggest that the addition of a 
single low-dose PQ (0.25  mg/kg) does neither compro-
mise the treatment outcome nor interfere with parasite 
clearance of AL.
Previous studies have reported selection of Pfmdr1 N86 
and Pfcrt K76 among recurrent infections during follow-
up after AL treatment [23–25], and also between enrol-
ment and day 3 [26]. A similar selection was not observed 
in the present study. This may be due to that there has 
been a temporal selection of Pfmdr1 N86 and Pfcrt K76 
in the study area ever since AL was introduced as first-
line treatment of uncomplicated malaria in 2006 [27], 
which has resulted in an overall higher baseline preva-
lence of the two alleles in recent years, which in turn may 
mask the selection potential of lumefantrine on these 
drug tolerance/resistance markers. Importantly, adding a 
single 0.25  mg/kg dose of PQ to AL did not apparently 
increase the selection potential of AL on Pfmdr1 N86 and 
Pfcrt K76, neither during the early treatment phase nor 
among recurrent infections during follow-up after treat-
ment. Thus, the findings suggest that addition of this sin-
gle low-dose PQ (0.25  mg/kg) does not apparently spur 
the selection potential of drug resistance markers previ-
ously associated with lumefantrine tolerance/resistance.
Table 2 Treatment outcome
ACPR adequate clinical and parasitological response





Early treatment failure 0 0
Late clinical failure 2 (1.8 %) 6 (5.8 %) 0.16
Late parasitological failure 5 (4.7 %) 2 (1.9 %) 0.45
Crude cure rate by day 28 100 (93.5 %) 96 (92.3 %) 0.73
Uncertain PCR outcome by day 
28
2 (1.9 %) 2 (1.9 %)  1.0
PCR‑determined re‑infection rate 
by day 28
5 (4.7 %) 5 (4.8 %) 0.95
Recrudescence 0 1 (1.0 %) 0.49
PCR‑adjusted ACPR by day 28 105 (100.0 %) 101 (99.0 %) 0.31
Fig. 2 Kaplan‑Meier survival curve for cure rate of subjects treated 
with AL + PQ and AL
Fig. 3 Microscopy‑determined parasite clearance following treat‑
ment with AL + PQ and AL
Fig. 4 Fever clearance following treatment with AL + PQ and AL
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The study has some potential limitations including that 
it involved patients of all ages with all levels of parasi-
taemia despite the WHO recommendation to conduct 
efficacy studies in children under the age of 5 years with 
parasitaemia level of 2000–200,000/µl of blood in highly 
malaria-endemic countries such as Tanzania, to mini-
mize the influence of immunity on treatment outcome 
in older individuals. However, this study was done to 
assess whether adding PQ to AL would potentially com-
promise the efficacy of latter drug probably due to drug–
drug interaction, that can be done at all ages and levels of 
parasitaemia.
Conclusion
The new WHO recommendation of adding a single low-
dose (0.25 mg/kg) of PQ to AL did not compromise treat-
ment outcome of uncomplicated P. falciparum malaria in 
Tanzania. The findings support the use of a single low-
dose of PQ together with AL as a potential component of 
ongoing P. falciparum malaria elimination efforts.
Additional file
Additional file 1. Artemether‑lumefantrine + primaquine versus 
artemether‑lumefantrine dataset.
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Table 3 Pfmdr1 N86Y and Pfcrt K76T distribution on day 0, 




 Pfmdr1 N86 91 (85.8 %) 92 (85.9 %) 0.49
86Y 11 (10.4 %) 8 (7.5 %) 0.45
N86Y 4 (3.8 %) 7 (6.5 %) 0.54
 Pfcrt K76 97 (95.1 %) 101 (98.1 %) 0.49
76T 1 (0.9 %) 0 (0 %) 0.71
K76T 4 (3.9 %) 2 (1.9 %) 0.44
Day 3
 Pfmdr1 N86 15 (65.2 %) 20 (76.9 %) 0.59
86Y 2 (8.6 %) 2 (7.7 %) 0.54
N86Y 6 (26.1 %) 4 (15.4 %) 0.48
 Pfcrt K76 24 (85.7 %) 27 (96.4 %) 0.24
76T 2 (7.1 %) 0 (0 %) 0.6
K76T 2 (7.1 %) 1 (3.6 %) 0.6
Day of recurrent parasitaemia
 Pfmdr1 N86 2 (66.7 %) 6 (85.7 %) 0.28
86Y 0 (0 %) 0 (0 %) –
N86Y 1 (33.3 %) 1 (14.3 %) 1.0
 Pfcrt K76 2 (100 %) 4 (80 %) 0.68
76T 0 (0 %) 0 (0 %) –
K76T 0 (0 %) 1 (20 %) 1.0
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